Medtronic Raises 2027 Forecasts Amid Strong Heart Device Demand

Medtronic, a leading player in the medical technology sector, has revised its fiscal 2027 forecasts upwards, citing strong demand for its heart devices used in complex cardiovascular procedures. The company has increased the lower end of its adjusted per share profit forecast to $5.94, up from $5.90, while maintaining the upper end at $6. Annual organic revenue growth is now expected to be between 7.25% and 7.75%, up from the previous projection of 6.75% to 7.25%.

Strategic Investments in Heart Devices

The company announced a significant $80 million investment in Pi-Cardia, a maker of heart-valve repair devices, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device in select markets outside the U.S. These strategic moves are part of Medtronic's broader focus on expanding its presence in high-growth segments of the medtech industry.

CEO Geoff Martha emphasized the importance of these investments during a post-earnings call, highlighting the company's confidence in the breadth of performance across its businesses and the increasing contributions from newer growth platforms. Martha noted that the penetration of soft tissue robotic surgery in emerging markets remains below 1%, presenting significant growth opportunities.

Financial Performance and Market Outlook

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by the company's pulsed field ablation portfolio, which saw an impressive 88% increase, used for treating irregular heart rhythms. For the quarter, Medtronic posted an adjusted per share profit of $1.45 on revenues of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

The company's Chief Financial Officer, Thierry Pieton, mentioned that Medtronic received tariff refunds that nearly covered the duties paid during the quarter; however, these potential future refunds have not been factored into the company's current outlook.

Martha reiterated Medtronic's commitment to prioritizing higher growth segments within the medtech industry, focusing on large patient pools and significant market segments. This strategic focus is expected to bolster the company's growth trajectory in the coming years.